Health
All coverage →LATEST REPORTS
Public Company Reports
LATEST 5
Intellia Therapeutics (NASDAQ: NTLA): Can CRISPR Deliver Its First Blockbuster?
Intellia Therapeutics · NTLARead report →
Fortress Biotech (NASDAQ: FBIO): Building a Biotech Empire—One Deal at a Time
Fortress Biotech · FBIORead report →
Neuronetics (NASDAQ: STIM): Building an Integrated Mental Health Treatment Platform
Neuronetics · STIMRead report →
Clover Health (NASDAQ: CLOV): CEO Andrew Toy Signals the AI-Care Model Is Moving From Turnaround to Compounding Earnings Power
Clover Health · CLOVRead report →Private Company Reports
LATEST 0No private reports in this selection yet.
News Signals
All news →Liquidia: Company highlighted additional portfolio data at pulmonary hypertension meetings
Why it matters Evidence generation is becoming a central part of the commercial moat.
Read the signal →Intellia Therapeutics: Additional Phase 3 HAELO results presented; manuscript published in NEJM
Why it matters Confirmed broad endpoint strength: 87% attack reduction, 89% fewer treated attacks and 91% fewer moderate/severe attacks.
Read the signal →Neuronetics: New real-world NeuroStar data presented at the Clinical TMS Society meeting
Why it matters The expanding evidence base can support physician adoption, payer discussions and broader treatment protocols. The adolescent and maintenance-treatment findings could also expand the long-term commercial opportunity.
Read the signal →Neuronetics: Robert Greene appointed Senior Vice President of Sales
Why it matters Neuronetics needs stronger NeuroStar utilization as well as new system placements. Greene’s experience in capital equipment and service-based healthcare sales makes this an important execution hire for rebuilding the commercial engine.
Read the signal →Neuronetics: Neuronetics partners with ANT Neuro on neuronavigation
Why it matters MRI-guided targeting and real-time tracking could strengthen NeuroStar’s competitive position among sophisticated TMS practices. Neuronetics can introduce the technology across an already large installed base rather than building a new network from scratch.
Read the signal →Intellia Therapeutics: Q1 results and business update
Why it matters Runway extended into at least 2028; R&D spending declined while commercial investment increased.
Read the signal →CEO Interviews
COMING SOONThe leaders behind the companies.
Conversations about vision, strategy and what comes next.